
Opinion|Videos|August 16, 2024
Navigating the Treatment Paradigm for Vitiligo: Efficacy, MOA, and Long-Term Use of FDA-Approved Topical Ruxolitinib
Author(s)Ted Lain, MD, MBA, FAAD
Ted Lain, MD, MBA, FAAD discusses navigating the treatment paradigm for vitiligo.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen
2
Social Media Mythbusters: Hypochlorous Acid Sprays
3
Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy
4
SkinJect Advances into Registrable Development as Potential First-in-Class Therapy for Gorlin Syndrome
5













